Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Theravance Biopharma, Inc. (TBPH)
|
Add to portfolio |
|
|
|
| Price: |
$20.58
| | Metrics |
| OS: |
52.8
|
M
| |
210
|
% ROE
|
| Market cap: |
$1.09
|
B
| |
226
|
% ROIC
|
|
Net cash:
|
$167
|
M
| |
$3.17
|
per share
|
|
EV:
|
$919
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($65.5)
|
M
| |
|
|
|
EBIT
|
($68.0)
|
M
| |
|
|
| EPS |
($1.03)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
| Date Filed | Type | Description |
| 08/24/2023 |
4
| Farnum Rhonda (SVP, COMM & MEDICAL AFFAIRS) has filed a Form 4 on Theravance Biopharma, Inc. |
| 08/22/2023 |
4
| Winningham Rick E (CEO) has filed a Form 4 on Theravance Biopharma, Inc. |
| 08/22/2023 |
4
| Sawaf Aziz (SVP & CFO) has filed a Form 4 on Theravance Biopharma, Inc. |
| 08/22/2023 |
4
| Grimaud Brett A. (SVP, GEN COUNSEL AND SECRETARY) has filed a Form 4 on Theravance Biopharma, Inc. |
| 08/22/2023 |
4
| GRAHAM RICHARD A (SVP, RESEARCH & DEVELOPMENT) has filed a Form 4 on Theravance Biopharma, Inc. |
| 08/22/2023 |
4
| Farnum Rhonda (SVP, COMM & MEDICAL AFFAIRS) has filed a Form 4 on Theravance Biopharma, Inc. |
| 08/15/2023 |
4
| GRAHAM RICHARD A (SVP, RESEARCH & DEVELOPMENT) has filed a Form 4 on Theravance Biopharma, Inc. |
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 51.3 | 55.3 | 71.9 | 73.4 | 60.4 | 15.4 | 48.6 | 42.1 |
| Revenue growth | -7.2% | -23.0% | -2.1% | 21.6% | 292.4% | -68.4% | 15.5% | 260.4% |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.7 | 6.0 | 2.9 | 4.7 |
| Gross profit | 51.3 | 55.3 | 71.9 | 73.4 | 59.7 | 9.4 | 45.8 | 37.5 |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 98.8% | 60.8% | 94.1% | 88.9% |
| Selling, general and administrative | 67.1 | 99.3 | 108.5 | 106.1 | 97.1 | 95.6 | 84.5 | 90.2 |
| Research and development | 63.4 | 193.7 | 261.0 | 219.2 | 201.3 | 173.9 | 141.7 | 129.2 |
| EBIT | -79.1 | -237.6 | -297.6 | -218.2 | -227.6 | -260.0 | -180.5 | -181.9 |
| EBIT margin | -154.1% | -429.6% | -414.2% | -297.2% | -377.0% | -1689.5% | -371.0% | -431.8% |
| Pre-tax income | -92.8 | -265.2 | -303.3 | -241.7 | -226.1 | -271.7 | -180.6 | -181.3 |
| Income taxes | 0.0 | -0.2 | -8.5 | -5.2 | -10.6 | 13.7 | 10.1 | 1.0 |
| Tax rate | | 0.1% | 2.8% | 2.2% | 4.7% | | | |
| Earnings from continuing ops | -92.8 | -265.1 | -294.8 | -236.5 | -215.5 | -285.4 | -190.7 | -182.2 |
| Earnings from discontinued ops | 965.0 | 65.6 | 16.8 | | | | | |
| Net income | 872.1 | -199.4 | -278.0 | -236.5 | -215.5 | -285.4 | -190.7 | -182.2 |
| Net margin | 1698.5% | -360.6% | -386.9% | -322.1% | -357.0% | -1855.0% | -391.9% | -432.6% |
| |
| Diluted EPS | ($1.26) | ($3.82) | ($4.73) | ($4.25) | ($3.91) | ($5.31) | ($4.26) | ($5.34) |
| Shares outstanding (diluted) | 73.6 | 69.5 | 62.3 | 55.6 | 55.1 | 53.7 | 44.7 | 34.2 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|